两种抗菌药物治疗成人社区获得性肺炎的临床疗效及成本-效果分析

Analysis of clinical efficacy and cost-effectiveness of two antibiotics in the treatment of adult community-acquired pneumonia

目的对比两种抗菌药物治疗成人社区获得性肺炎(CAP)的临床疗效及成本差异,从药物经济学角度为临床实践提供参考。方法 127例成人CAP患者,根据治疗方案的不同分为观察组(76例)和对照组(51例)。观察组采用头孢噻肟/舒巴坦治疗,对照组采用头孢哌酮/舒巴坦治疗。对比两组患者的临床疗效,成本-效果比值(C/E),不良反应发生情况。结果观察组患者的有效率为90.79%,与对照组的92.16%对比,差异无统计学意义(P>0.05)。观察组的C/E为36.47,优于对照组的61.15。观察组患者的不良反应发生率为5.26%,与对照组的3.92%对比,差异无统计学意义(P>0.05)。结论头孢噻肟/舒巴坦是用于治疗成人CAP最经济有效的方案。

Objective To compare the clinical efficacy and cost-effectiveness of two antibiotics in the treatment of adult community-acquired pneumonia(CAP),and provide reference for clinical practice in pharmacoeconomics.Methods A total of 127 adults with CAP were divided into observation group(76 cases)and control group(51 cases)according to different treatment regimens.The observation group was treated with cefotaxime/sulbactam,and the control group was treated with cefoperazone/sulbactam.The clinical efficacy,cost-effectiveness ratio(C/E),and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 90.79%,which had no statistically significant difference compared with 92.16%of the control group(P>0.05).The C/E of the observation group was 36.47,which was better than 61.15 of the control group.The incidence of adverse reactions of the observation group was 5.26%,which had no statistically significant difference compared with 3.92%of the control group(P>0.05).Conclusion Cefotaxime/sulbactam is the most economical and effective treatment for adult CAP.